Trial Profile
An efficacy trial of intravitreal dexamethasone implant (Ozurdex) and intravitreal ranibizumab (Lucentis) in the treatment of macular edema (ME) caused by retinal vein occlusion
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Sep 2017
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ranibizumab (Primary)
- Indications Retinal oedema; Retinal vein occlusion
- Focus Therapeutic Use
- 25 Sep 2017 New trial record